Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Label indication AVONEX is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. AVONEX is for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. ( 1 ) FDA label
Also known as Avonex
Serum containing Avonex · 2 trials · 1 indication
| Arm | Type | Description |
|---|---|---|
| Active treatment | EXPERIMENTAL | Interferon treatment for MS |
| Sequence 1 | EXPERIMENTAL | Serum containing Avonex followed by serum free Avonex |
| Sequence 2 | EXPERIMENTAL | Serum free Avonex followed by serum containing Avonex |
| Name | Type | Description |
|---|---|---|
| Avonex | DRUG | Interferon treatment for MS |
| Serum containing Avonex | DRUG | 60mcg IM dose of serum containing Avonex on Day 1, followed by 60mcg IM dose of serum free Avonex on Day 15 |
| Serum Free Avonex | DRUG | 60mcg IM dose of serum free Avonex on Day 1, followed by 60mcg IM dose of serum containing Avonex on Day 15. |
Inclusion Criteria: * Ability to understand risks of study and provide informed consent. * Must be Chinese, aged 18 to 55 years inclusive at time of consent. * Must have diagnosis of relapsing MS of 3 months duration at time of screening visit. * Must have at least 1 documented MS attack within 3 y...
Top 17 of 21 competitors
Serum containing Avonex is an investigational small molecule being studied for the treatment of Multiple Sclerosis. It is currently in Phase 1 clinical development. The drug is being evaluated for its bioequivalence to a serum-free formulation of Avonex, which is used to treat this condition.
Serum containing Avonex is being developed by Biogen Inc., a biopharmaceutical company. Biogen's stock is traded under the ticker symbol BIIB on the NASDAQ exchange. The company is conducting clinical trials to evaluate this drug for the treatment of Multiple Sclerosis.
Serum containing Avonex is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The drug is being studied in healthy volunteers to assess its bioequivalence to a serum-free version of Avonex for the treatment of Multiple Sclerosis.
Serum containing Avonex has one completed clinical trial registered under NCT00913250, titled "A Bioequivalence Study of Serum Free Avonex and Serum Containing Avonex in Healthy Volunteers." This Phase 1 study enrolled 96 participants and was a controlled, randomized trial, though it was not double-blind.
Serum containing Avonex is a formulation of Avonex that includes serum, while Avonex is typically a serum-free formulation. The drug is being studied to determine if the serum-containing version is bioequivalent to the standard serum-free Avonex for the treatment of Multiple Sclerosis.